The objective of this study was to compare quality of life and incidence of dry persistent cough among patients treated with eprosartan and enalapril for mild-moderate hypertension. This was a randomised 26-week doubleblind controlled trial carried out in clinics in nine countries of North America, Europe and South Africa. A total of 529 patients aged 18 and over with diastolic blood pressure between 95 mm Hg and 114 mm Hg were studied. Treatment comprised of eprosartan or enalapril monotherapy for 12 weeks with the option of hydrochlorothiazide addition for the remaining 14 weeks. The primary outcome measures were cough and the Psychological General Wellbeing Index (PGWB) total and subscales (anxiety, self-control, depression, general health, positive wellbeing and vitality). The results
Introduction
ACE-inhibitor drugs for essential hypertension are effective at lowering blood pressure but are known for producing a dry unproductive tickly cough [1] [2] [3] [4] [5] which may reduce quality of life. 6 As high blood pressure is often symptomless and its treatment involves daily life-long medication, the quality of life of patients while on the drugs is an important factor in the choice of drug and may influence compliance. 7, 8 Although studies have compared earlier generations of drugs, including enalapril, [9] [10] [11] [12] [13] and cough side-effects of nonpeptide angiotensin-II (AII) receptor antagonist, [14] [15] [16] [17] [18] there is little information about other aspects of quality of life on them receptor antagonist. 22 One hypothesised advantage of this generation of drugs is reduction in the adverse effect of cough. The objective of this trial was to compare the quality of life, including the incidence of persistent non-productive cough, in mild-to-moderately hypertensive patients treated with eprosartan and enalapril.
Methods
Patients aged 18 or more with sustained mildmoderate hypertension were eligible for the trial (mean sitting diastolic blood pressure (DBP) between 95 mm Hg and 114 mm Hg inclusive at three successive visits). The 41 centres in the study were situated in nine countries. Ethical approval was obtained from the relevant authorities at the London School of Hygiene and Tropical Medicine Ethics Committee and at each centre; patients provided written consent to participate in the trial.
Patients were screened before entering a 3-5 week placebo run-in period. Eligible patients were randomised to treatment with either eprosartan 200 mg twice daily or enalapril 5 mg once daily. Doses were titrated over an 18 week period up to a possible maximum of 300 mg eprosartan twice daily or 20 mg enalapril once daily. To ensure 'blinding', placebo forms of the second drug were given alongside the active drug. After 12 weeks patients on maximum dose of the medication could be prescribed the diuretic hydrochlorothiazide (HCTZ) openly, the initial dose being 12.5 mg once daily, later doubled if necessary. Finally, there was an 8-week maintenance period.
The main clinical outcomes were dry unproductive persistent cough assessed by the investigator using a questionnaire, and control of blood pressure (reduction of sitting DBP to less than 90 mm Hg or a reduction to less than 100 mm Hg if this was at least 10 mm Hg below baseline value). Based on evidence available at the time, the sample size was set to detect a difference of 7% between treatments in the incidence of dry cough, with 90% power at a significance level of 5%. The clinical outcomes are reported elsewhere. [23] [24] [25] The primary quality of life outcomes were selfassessed dry unproductive persistent cough and the Psychological General Wellbeing Index (PGWB) 26 with six subscales. This well-validated instrument 27, 28 has been used in international studies investigating the effects of antihypertensives on quality of life. 29 The study had 80% power to detect a standardised difference 30 of 0.3 or more on the PGWB subscales at a significance level of 1%. The secondary outcomes, separate from the PGWB, were sleep disturbance score, 31, 32 satisfaction with life, job satisfaction score, 33 postural hypotension 34 and prevalence of 27 symptoms.
A self-completion quality of life questionnaire was given to patients at up to five clinic visits: at screening; at entry into the double-blind trial; at the second and fourth visits during the titration period (weeks 6 and 12); and at the final evaluation visit (week 26 for those who completed, otherwise the visit at which they withdrew or a follow-up visit). To avoid any influence from the clinician, the protocol prescribed that the patient complete the questionnaire in privacy before seeing the clinician and that the clinic nurse seal each questionnaire in an envelope in the presence of the patient. The questionnaire was translated into the primary language of each centre and checked by back-translation. Patients not literate in the primary language of their centre were excluded. SAS version 6.08 for Windows 3.1 and Stata Version 5 were used for the analyses which were done without knowledge of the treatment codes. Primacy was given to analysis by intention-to-treat with a per-protocol analysis as a subsidiary evaluation. Study end point was defined as the time that the patient left the trial. The last questionnaire completed by the patient was used in the analyses, even if done at a follow-up visit or before the end of treatment. The monotherapy end point was week 12 of the treatment period, the visit at which HCTZ could first be prescribed. If there was no questionnaire for this visit then the most recent questionnaire was used. Patients included in the per protocol analysis had completed all five questionnaires and the clinician assessed that they had completed the treatment period, but not necessarily complied strictly with pill-taking. Incidence of cough by an end point is defined as the percentage of those without cough at baseline who acquired a cough by the end-point. To cater for incomplete information, coughs were defined as definite, probable or possible (Table 1) . Cough outcomes were compared by chi-squared test.
If patients had missed fewer than 20% of items on a PGWB scale their scores were increased by the ratio of the total number of questions in the scale to the number of questions answered by the individual. Patients with at least 20% of items on a scale missing were excluded from analysis of that scale. The wellbeing scores were highly skewed towards the 'best' value but the changes in scores were closer to the normal distribution. The change in quality of life score attributable to the treatment was estimated from a model using change in score as the outcome and treatment as the exposure with the logarithm of the baseline score as covariate. Logarithms were used to overcome the problem of skewed baseline values. The model also included the square of log (baseline score) as this improved the fit of the model (using an F test). Where there was statistically significant interaction between treatment and baseline values, separate models were run for baseline values above and below the point at which the response curves for the two treatments crossed over.
Results
A total of 265 patients were randomised to eprosartan and 264 to enalapril. Six patients were excluded from all analyses owing to lack of baseline and/or end point questionnaires, leaving 261 patients randomised to eprosartan and 262 patients to enalapril. Screening questionnaires were used as baseline questionnaires for five patients (three eprosartan and two enalapril). Fifteen patients did not complete a questionnaire at the end of treatment so an earlier one was used. There were 181 patients eligible for the per protocol analysis from the eprosartan group (68.3%) and 174 from the enalapril group (65.9%). Thirty-five (13.2%) patients withdrew from the eprosartan arm and 47 (17.8%) from the enalapril arm (P ϭ 0.15). Of these, five were excluded from the analyses because of non-completion of questionnaires. Only two patients on eprosartan and seven on enalapril were withdrawn specifically because of an adverse experience of cough.
At baseline, the two treatment groups were alike in demographic characteristics, key clinical and behavioural indicators, and scores on the quality of life scales (Table 2) . Males accounted for 57% of the eprosartan patients and 56% of the enalapril ones. The average ages were 55.5 years and 55.9 years and the mean DBPs were 100.7 mm Hg and 101.1 mm Hg for the two groups respectively. Over 80% of both groups had previously used antihypertensives but slightly more of the eprosartan than enalapril patients had previously used ACE inhibitors (60.0% against 53.1%) and previously had ACE coughs (10.4% against 6.5%). Similar percentages smoked (13.8% on eprosartan and 12.2% on enalapril). Table 3 shows that those on enalapril were twice as likely to have gained a definite or possible cough by
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Journal of Human Hypertension study end point as those on eprosartan (7.6% vs 3.2%) P ϭ 0.099. At monotherapy end point the differences were greater (9.9% vs 2.1%) and of clear statistical significance, P ϭ 0.001. Among those who fulfilled the per protocol criteria the prevalence and incidence of cough were slightly less than for the intention-to-treat analysis for study and monotherapy end points. As for the intention-to-treat analyses, the treatment differences in incidence by study end point were not statistically significant (P ϭ 0.144) but were at monotherapy end point (P ϭ 0.002).
The main purpose of this paper was to consider patients' own perceptions. Clinical investigators' definitions of cough differed from self-assessed cough in two ways: first, the investigator had to judge that the cough was not of bacterial or viral origin and second, the duration of the cough was calculated not just up to the time of visit but up to the time it disappeared. Of 15 patients identified by either the investigator or the patient as having a cough at baseline, only two were identified by both. At study end point 20 out of 34 reported coughs were in common The incidences of cough by study end point according to the investigators' questionnaires were 2.0% definite cough, 5.1% probable/ possible cough for enalapril, 0.4% and 2.4% respectively for eprosartan ( 2 (2df) ϭ 5.449, P ϭ 0.06).
PGWB
Three of the six subscales (anxiety, depression, and self-control) showed small negative mean changes between baseline and study end point for eprosartan but otherwise all the point estimates for withintreatment change were positive for both treatments (ranging from absolute values of 0.06 to 0.72 for subscales and being 0.04 and 2.52 for total PGWB for eprosartan and enalapril, respectively; detail not shown).
Observed differences between treatments in changes in PGWB score suggested that eprosartan might have some advantage (Table 4) . After adjusting for baseline values a clear effect remained for self-control (P ϭ 0.02) at study end point (Table 5) . Small between-group differences for anxiety (P ϭ 0.08) and general health (P ϭ 0.06) were not statistically significant. Interaction tests showed that the treatment effect for study end point differed according to the baseline values for positive wellbeing, vitality and total score. Of these there was a statistically significant advantage for enalapril for the total score if the baseline value was no greater than 119 out of 132 (83% of all patients at baseline). At monotherapy end point there were no significant differences between treatments (not shown).
The per-protocol results (not shown) were consistent with those for the intention-to-treat analysis: the treatment difference for change for self-control was −0.35 (P ϭ 0.07) and for total PGWB if baseline score Anxiety (5 a In the regression model change in score was the outcome, treatment the exposure, and log (baseline score) log 2 (baseline score) the covariates.
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was up to 119 the treatment effect was −2.67 (P ϭ 0.03).
The end point values of scores for life satisfaction, sleep disturbance and job satisfaction were similar in the two treatment groups (not shown). The symptoms reported by over 10% of patients were having to get up at night to pass urine, head pains or headaches, and pain in joints of hands. The mean number of symptoms reported was the same for both treatments, being 2.0 at baseline (s.d. 3.0) and 1.8 at study end point (s.d. 2.9).
Discussion
Incidence of dry cough (definite or probable/possible) among the enalapril group was four times that among the eprosartan group at monotherapy end point and twice as great at study end point, the latter estimate not being statistical significance. The evidence for less cough on ACE-II antagonists agrees with studies comparing other ACE-II antagonists with enalapril during a 12-week trial 35, 36 and with lisinopril among people with a history of ACE-inhibitor related cough. 18, 37 In the present study there were fewer people with coughs than anticipated. The expected incidence of 2% with definite non-productive persistent cough for eprosartan and 9% for enalapril was close to the combined incidence of definite, probable and possible coughs at monotherapy end point and higher than any other estimates. Part of the explanation for few definite coughs may be that approximately 12% of patients gave incomplete answers. Also, 16 patients who reported a cough at one visit during the double-blind period did not report it at a subsequent one. ACE coughs could disappear spontaneously during treatment 38 or patients may cease to report a cough because they become tolerant to it. The estimates of ACE-induced cough vary widely between studies, as do the means of assessing cough and the populations covered. In double-blind randomly controlled trials the net increase over baseline ranged between 13% and 25%, 6 all higher than found in this study. The criteria used to define cough in this study were unusually stringent.
Mean baseline values of total PGWB were compa-rable with those found in other studies of hypertensives in Europe and the US 19, 20, 29, 39 and the subscale means tallied with those found at baseline in a similar study. 13 The favourable effects of enalapril compared with eprosartan on self-control and total score were seen at study end point but not at monotherapy end point. Thus, the main improvements in quality of life might come after some weeks on treatment. As the percentages of patients using HCTZ were almost identical the addition of a diuretic is unlikely to account for this result.
In a study of similar design that compared cilazapril with atenolol and nifedipine, changes in PGWB total scale tended to be more positive by week 24 than they had been at week 12. 29 However, in a study comparing enalapril with amlodopine most of the benefit manifested in PGWB and subscale scores came in the titration period of 12 weeks. 13 In the few studies which report scores for PGWB subscales results have been mixed with ACE I inhibitors showing some quality of life improvements but not always to a greater extent than the comparator drugs. 11, 13, 29, 39 Enalapril has not previously been reported as having an advantage in self-control. One other study reporting PGWB results for ACE II drugs 21 showed significant within-treatment improvements for losartan for four of the six PGWB subscales in a 12-week study of losartan and amlodopine. However, self-control was one of the subscales without any improvement.
In two studies comparing quality of life for losartan with nifedipine GITS 19 and amlodopine 20 respectively there were no significant between-treatment differences in PGWB total, sleep disturbance, sexual function, social functioning, cognitive functioning and overall health perception. The smaller scale and shorter duration of these studies would not account for the null finding, as the observed differences were very small. The only difference found (in losartan's favour) was in reported oedema.
In the absence of a placebo group it is difficult to gauge the importance of the changes which can be ascribed to individual treatments. Our interpretation is based on relative differences between treatments in their effects on quality of life. Effect size 'standardises' treatment differences by dividing the difference by standard deviation. An effect size of 0.3 is conventionally considered as small, one of 0.5 as moderate and one of at least 0.8 as substantial. 40 The effect size of self control and total PGWB were of the order of 0.2. The 95% confidence bounds include effect sizes around 0.3 favouring enalapril at one extreme (0.36 self-control and for the total PGWB score) and negligible between-treatment effect sizes at the other extreme (0.02, 0.09 respectively).
Although small, the between-drug effect sizes for self-control and total PGWB are of the same order of magnitude favouring captopril observed in a study comparing total PGWB for captopril and propranolol (the subscales were not reported). In other trials
Journal of Human Hypertension which have compared ACE inhibitors with newer beta-blockers (eg atenolol) or calcium channel blockers the between-drug effect sizes for the total score were 0.04 or less. 41 In summary, those on enalapril were more likely than those on eprosartan to develop a persistent dry cough by the monotherapy end point, a disadvantage which appeared to moderate by study end point. On the other hand, enalapril appeared to have a slight advantage over eprosartan in measures of self-control and total PGWB score (if the patient was not already at the high end of the scale), particularly for those who stayed in the trial beyond monotherapy end point. The effect sizes of around 0.2 were of the same order of magnitude as those found for overall PGWB between captopril and propranolol and larger than those observed in other trials comparing ACE inhibitors with a range of other antihypertensive agents. It is concluded there are small but real differences in the quality of life of patients on the two treatments.
